Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Teitelbaum

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancer|January 26, 2011
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaWeijing Sun, Davendra Sohal, Daniel G Haller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinomaD P S Sohal, K Mykulowycz, T Uehara, et al.
The Oncologist|May 13, 2022
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal CancerThomas B Karasic, Timothy J Brown, Charles Schneider, et al.
Pancreas|September 14, 2017
Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective AnalysisBryson W Katona, Giorgio A Roccaro, Michael C Soulen, et al.
Science (New York, N.Y.)|March 26, 2011
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansGregory L Beatty, Elena G Chiorean, Matthew P Fishman, et al.
Science (New York, N.Y.)|October 2, 1998
An antimicrobial activity of cytolytic T cells mediated by granulysinS Stenger, D A Hanson, R Teitelbaum, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2013
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancerDavendra P S Sohal, James M Metz, Weijing Sun, et al.
Frontiers in Oncology|July 22, 2022
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing <i>DPYD</i> and <i>UGT1A1</i> Screening to Guide Chemotherapy DosingLisa A Varughese, Madhuri Bhupathiraju, Glenda Hoffecker, et al.
JAMA Oncology|May 24, 2019
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical TrialThomas B Karasic, Mark H O'Hara, Arturo Loaiza-Bonilla, et al.
JCO Precision Oncology|August 7, 2025
Implementation of <i>DPYD</i> and <i>UGT1A1</i> Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical TrialSony Tuteja, Mari Angelica S Cayabyab, Glenda Hoffecker, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer|January 26, 2011
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaWeijing Sun, Davendra Sohal, Daniel G Haller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinomaD P S Sohal, K Mykulowycz, T Uehara, et al.
The Oncologist|May 13, 2022
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal CancerThomas B Karasic, Timothy J Brown, Charles Schneider, et al.
Pancreas|September 14, 2017
Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective AnalysisBryson W Katona, Giorgio A Roccaro, Michael C Soulen, et al.
Science (New York, N.Y.)|March 26, 2011
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansGregory L Beatty, Elena G Chiorean, Matthew P Fishman, et al.
Science (New York, N.Y.)|October 2, 1998
An antimicrobial activity of cytolytic T cells mediated by granulysinS Stenger, D A Hanson, R Teitelbaum, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2013
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancerDavendra P S Sohal, James M Metz, Weijing Sun, et al.
Frontiers in Oncology|July 22, 2022
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing <i>DPYD</i> and <i>UGT1A1</i> Screening to Guide Chemotherapy DosingLisa A Varughese, Madhuri Bhupathiraju, Glenda Hoffecker, et al.
JAMA Oncology|May 24, 2019
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical TrialThomas B Karasic, Mark H O'Hara, Arturo Loaiza-Bonilla, et al.
JCO Precision Oncology|August 7, 2025
Implementation of <i>DPYD</i> and <i>UGT1A1</i> Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical TrialSony Tuteja, Mari Angelica S Cayabyab, Glenda Hoffecker, et al.
Pageof 4